Shanghai Yiweikang Pharmaceutical Co. Ltd. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, inflammatory and immunological disorders.